Premium
Parotid salivary basic proline‐rich proteins inhibit HIV‐1 infectivity
Author(s) -
Robinovitch MR,
Ashley RL,
Iversen JM,
Vigoren EM,
Oppenheim FG,
Lamkin M
Publication year - 2001
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1034/j.1601-0825.2001.70204.x
Subject(s) - saliva , proline , infectivity , ion chromatography , size exclusion chromatography , amino acid , molecular mass , hela , biochemistry , chemistry , gel permeation chromatography , recombinant dna , affinity chromatography , biology , virus , in vitro , virology , enzyme , gene , organic chemistry , polymer
OBJECTIVE: The objective of this study was to investigate the molecular nature, spectrum of activity and mechanism(s) of action of those human parotid basic proline‐rich proteins that exhibit anti‐HIV‐1 activity. DESIGN: Fractions containing the basic proline‐rich proteins were obtained from human parotid saliva of presumed HIV‐1 non‐infected human subjects and characterized with respect to their purity, apparent molecular size and their ability to inhibit the infectivity of T‐tropic and M‐tropic strains of HIV‐1. SUBJECTS, MATERIALS AND METHODS: Stimulated parotid saliva samples were collected from human subjects who denied having any risk factors for HIV‐1 infection and whose parotid salivas inhibited HIV‐1 infectivity. Such samples were subjected to affinity, molecular sieve and ion exchange chromatography to isolate individual salivary components. Those fractions demonstrating anti‐HIV‐1 activity were analyzed by SDS‐PAGE in order to assess their purity and determine their apparent molecular weights. HIV‐1 inhibitory activity was determined using HIV‐1 strains LAI and BaL in a Hela cell‐derived multinuclear activation of a galactosidase indicator (MAGI) assay. Amino acid analyses were performed on some fractions. RESULTS: Recombinant gp120‐CH‐Sepharose chromatography of one subject's parotid saliva revealed specific binding of human parotid basic proline‐rich proteins, most prominently one with an apparent molecular weight of 37 kDa. Molecular sieve and cation exchange chromatography yielded a fraction greatly enriched in this protein which amino acid analysis confirmed was proline‐rich. A similar fraction from two other subjects also contained basic proline‐rich proteins of similar molecular size. These fractions inhibited both T‐tropic and M‐tropic strains of HIV‐1 when assayed in the MAGI system. Since SLPI activity is not observable in the MAGI assay, this inhibition was not due to SLPI. The presence of thrombospondin‐1 (TSP‐1) in the active fractions was precluded on the basis of SDS‐PAGE examination. CONCLUSIONS: Specific basic proline‐rich proteins in human parotid saliva possess significant anti‐HIV‐1 activity independent of that attributable to SLPI or TSP‐1. Since the inhibition is detectable with the MAGI assay, its mechanism of action involves virus‐host cell interaction prior to the introduction of the tat gene product into the host cell and may be through the binding of the basic proline‐rich proteins to the HIV‐1 gp120 coat of the virus.